April 15, 2021
Japan’s all-important reimbursement policy panel on April 14 agreed to apply drug pricing rules for Celgene’s Breyanzi (lisocabtagene maraleucel; liso-cel), the third CAR-T cell therapy approved in the country. Breyanzi was approved on March 22 under the category of “regenerative...read more